Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

BMD preserved with investigational drug for uterine fibroid bleeding

Key clinical point: Bone mineral density appears not to be compromised with relugolix combination therapy.

Major finding: The mean change in lumbar spine bone mineral density was –0.36% and –0.13% from baseline to 24 weeks in two trials.

Study details: Two phase 3, randomized trials in women with uterine fibroids and heavy menstrual bleeding enrolled almost 800 women.

Disclosures: The trials were funded by Myovant Sciences. The lead author disclosed that he has served as a consultant/advisory board member and speaker for Amgen and a consultant/advisory board member for Myovant. Several of his coauthors disclosed employment and ownerships interests in Myovant.


McClung MR et al. Obstet Gyncol. 2020 May. doi: 10.1097/01.AOG.0000662944.34860.b4.